Status:
COMPLETED
Alkali Therapy in Chronic Kidney Disease
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Conditions:
Chronic Kidney Disease
Metabolic Acidosis
Eligibility:
All Genders
19+ years
Phase:
PHASE2
PHASE3
Brief Summary
Kidney disease is a common medical condition. Individuals with kidney disease develop a build-up of acid in their blood. This acid can affect their muscles, bones, glucose metabolism and kidneys. The ...
Eligibility Criteria
Inclusion
- Estimate GFR \<= 45 and \>15 ml/min/1.73m2
- Age \>18
Exclusion
- Previous chronic treatment with alkali within the last 3 months (including sodium bicarbonate, calcium carbonate or baking soda)
- bicarbonate level \<20 or \>25 mEq/L
- New York Heart Association Class III or IV heart failure
- Systolic blood pressure \>180 mmHg
- Initiation of ESRD treatment planned within 6 months
- Kidney transplantation
- Treatment with immunosuppressives within the last 3 months
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT01452412
Start Date
October 1 2011
End Date
August 1 2016
Last Update
January 7 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461
2
Case Western Reserve University
Cleveland, Ohio, United States, 44106